Justin Yoo @emoryuniversity.bsky.social presents new advances in using Osivelotor and a new mobilizing reagent in increasing HSPC yield #ASCAT2026 @SheehanLab
Rimas Orentas
@cgtgaithersburg.bsky.social
Immunotherapy R&D - looking to develop immunotherapy, cell and gene therapy, and make an end to sickle cell disease.
John Tisdale delivering a master class in gene therapy for sickle cell disease #ASCT2026 from BMT to LNP based gene editors -we keep moving forward and look for outpatient global development @conquerscd.bsky.social @sctpn.bsky.social @ascaa.bsky.social @altnih4science.bsky.social #NHLBI
Here in London for the Academy for Sickle Cell and Thalssemia meeting. #ASCAT26. Still an uphill battle to get this platform established in bio-science meetings
My 1st science job was @BARC (Beltsville Agricultural Research Center) the @npr.org story today understated the scope of this center- it’s the NIH for agriculture with a critical mass of researchers advancing the field. As my lab chief used to say, NIH? Try living without food. @usdagov.bsky.social
Incredible facility in Baltimore -4MLK hosting Maryland Stem Cell Research Fund celebration. We heard the political will it took to follow the example of @cirmnews.bsky.social and make Maryland a place for innovation and cures. Thanks to Del. Rosenberg and Dr. Curt Civin for making this a reality
More great results with stacking Epocritamab with Rituximab in follicular lymphoma. So, a new generation anti-CD3xCD20 bispecific antibody plus established anti-CD19 antibody. #iwNHL26 these are early results and we need longer time observation. Amazing nevertheless
Stacking ADCs and bi-specific antibodies is showing really strong responses!! #iwNHL26 moreover the degree of tumor destruction is likely to increase antigen release and presentation
Dr. Gilles Salles @mskcc.bsky.social demonstrates mechanisms of resistance to anti-CD79B ADC. In general though, really effective. #iwNHL26
Dr Ahmet Dogan presenting at the 23rd International Workshop on NHL, presents a key question in T cell (and other) malignancies….are we treating cell state or cell of origin #iwNHL26
Asymmetric cell division explains why 4-1BBζ CAR-T cells preferentially generate durable memory progeny whereas CD28ζ CAR-T cells skew toward short-lived effector fates @natimmunol.nature.com @i3h-upenn.bsky.social www.nature.com/articles/s41... www.nature.com/articles/s41...
Spatial Orchestration of Skin Fibrosis by a CD8+ T cell-Myofibroblast Axis https://www.biorxiv.org/content/10.64898/2026.06.17.732787v1
10-Year Study Affirms Life-Changing Benefits of Hydroxyurea for Sickle Cell Anemia @cincyresearch.bsky.social scienceblog.cincinnatichildrens.org/10-year-stud... www.nejm.org/doi/full/10.... @nejm.org
10-Year Study Affirms Life-Changing Benefits of Hydroxyurea for Sickle Cell Anemia - Research Horizons
A 10-year study in Uganda shows hydroxyurea dramatically reduces complications and death from sickle cell anemia, offering hope for wider global treatment access.
scienceblog.cincinnatichildrens.org
Bhattacharya’s legacy The US had a “world-class Ebola lab in Frederick, Maryland, with the NIH,” designed to develop vaccines & treatments. The lab would normally be swinging into action. “But that lab was shuttered last year, with staff laid off abruptly”😢 www.theguardian.com/world/2026/m...
US is ‘simply choosing not to stop’ Ebola outbreak after massive public health cuts, experts say
Hundreds of cases reported in the DRC after USAID has been dismantled and key scientific research canceled
theguardian.com
So our anti-HIV CAR makes it to the NYT. LV from Miltenyi, funded by CIRM @cirmnews.bsky.social - article should also highlight Dr Abedi’s team @ucdavismedschool.bsky.social @ucdavis.bsky.social where patients are being treated. #HIVcure #HIV #ASGCT26 www.nytimes.com/2026/05/11/h...
A Single Infusion Could Suppress H.I.V. for Years, Study Suggests
nytimes.com
Carl June showing the impact of anti-FAP CAR-T cells in pancreatic cancer #AACR26 @upenn.edu #PanCan #CARTcell #immunotherapy Target the tumor stroma!
Thank you again @michaeldgreen.phd for speaking out. I don't know what bothers me more: Director Bhattacharya's callousness that damaging the careers of talented young scientists is "the cost of doing business" for his politics or His ignorance and lack of imagination about experimental design.
Made a short video as a response. 3 questions remain for me. 1) What is the definition of a "DEl activity," and how is it being communicated to NIH staff so they can determine whether a grant qualifies? (Continued below)
Ex vivo expanded allogeneic Vδ2 T cells specifically reduce reservoirs of HIV-1 following latency reversal #gdTcells @insight.jci.org
JCI Insight - Ex vivo expanded allogeneic Vδ2 T cells specifically reduce reservoirs of HIV-1 following latency reversal
doi.org
M Spencer Chapman showing Clonal hematopoiesis in old age with really deep and broad sequencing of somatic mutations #tandem26 @sangerinstitute.bsky.social post HSCT mapping shows clonal evolution and expansion -older donors have 10 fold less founding stem cell clones
Hopkins has a terrific book on student surveillance: www.press.jhu.edu/books/title/... @hopkinspress.bsky.social
Smart University
Student Surveillance in the Digital Age
press.jhu.edu
Thinking of how many Swedish doctors and researchers lionized this dipshit
This is a powerful line of questioning from Senator Hassan and an outrageous answer from Director Bhattacharya. "If there were disruptions then it is the responsibility of the researchers that were managing the patients, not the NIH" because "I ordered that ... there would be continuity of care."
Glimmers of hope to change the system and make curative therapy more broadly available #tandem26 great session on access with Drs Urbanio-Ispizua (Barcelona) Maziarz (Portland) thanks to Sumi, David, Anna and Jeff for the session as well
Dr M Walters presents BMT CTN Haplo Sickle Cell (Peds Arm). Good news, when it works it works. However Chronic GvHD remains a serious issue (30% at 2 years) as do high levels of infection, and even a few graft failures. #Tandem26 IMO- not ready to globalize,more refinement (or gene therapy) needed.
Watch this video if you want to cry over overwhelming decency rather than over rage about what some are trying to turn our country into.
A video of Alex Pretti reading out the final salute of an unnamed veteran he cared for until the end of his life in the ICU, posted to Facebook by his son.
Thanks to Orlando and the wonderful staff @ash.hematology.org #cscevents #OCCC #orangecountyconventioncenter - I lost my iPhone there-within 12 hours it was at the lost and found office after multiple hand-offs. This kind of service makes it a place you want to return to. Thank you! #ASH25
Mid-blowing data #ASH25 from MJ Friedrich -recreating a thymic environment in the liver via LNPs generated young T cell phenotype and this correlates to better response to checkpoint blockade in mouse tumor models and better vaccine responses @technologyreview.com @broadinstitute.org
Michelle Weeks presenting a Master Class in DNA sequencing at #ASH25 of over 4,000 #sicklecelldisease cases showing clonal hematopoiesis starts at infancy and increases to 7.1% by age 11 @danafarber.bsky.social drivers include TP53, ATM, PPMID, CHEK2 @ascaa.bsky.social @conquerscd.bsky.social
At one point or another, we're all going to need to see a doctor. But our health care system remains unaffordable, inaccessible, and deeply dysfunctional. It is unacceptable. That’s why a strong majority of Americans agree: We need Medicare for All.
Are you using the right tumor micro environment model? Cancer is a disease of aging @sitcancer.bsky.social #SITC25 great session at the annual meeting on the aged immune system and the tumor micro environment moderated by Drs DA and A Weeraratna.